Skip to main content

PanVera President to Pull Double Duty as Head of Aurora Biosciences

NEW YORK, March 14 - Vertex Pharmaceuticals on Thursday has appointed Michael Wokasch president of its Aurora Biosciences unit.


Wokasch is already president of another Vertex subsidiary, PanVera, and will retain that role. At Aurora, he replaces Harry Stylli, who left the firm.


Wokasch will help the company broaden its customer base and expand customer relationships, said Vertex chairman and CEO Joshua Boger in a statement.


Vertex acquired Aurora last year in order to expand its drug discovery in G-protein coupled receptor and ion channel genes.


PanVera is a recombinant protein manufacturer that Aurora snapped up in 2000 for about $36 million. Wokasch became PanVera's president in July 2001.


Prior to that, he was CEO and president of startup Gala Design.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.